KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 122 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 4.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $117,000 | -99.5% | 11,145 | -99.3% | 0.00% | -99.6% |
| Q4 2020 | $25,716,000 | +21.5% | 1,661,236 | +14.6% | 0.90% | -4.6% |
| Q3 2020 | $21,163,000 | +7.8% | 1,449,517 | +39.8% | 0.94% | +1.2% |
| Q2 2020 | $19,640,000 | +18.1% | 1,036,947 | +19.8% | 0.93% | -11.1% |
| Q1 2020 | $16,631,000 | +78.5% | 865,725 | +78.1% | 1.04% | +173.8% |
| Q4 2019 | $9,319,000 | -32.4% | 486,140 | -66.1% | 0.38% | -37.5% |
| Q3 2019 | $13,785,000 | +67.3% | 1,432,932 | +4.2% | 0.61% | +86.5% |
| Q2 2019 | $8,239,000 | +2.5% | 1,375,399 | -0.1% | 0.33% | +1.6% |
| Q1 2019 | $8,039,000 | -37.5% | 1,376,475 | +0.2% | 0.32% | -46.4% |
| Q4 2018 | $12,869,000 | +16.7% | 1,373,437 | +112.2% | 0.60% | +61.6% |
| Q3 2018 | $11,024,000 | +35.8% | 647,307 | +35.5% | 0.37% | +26.5% |
| Q2 2018 | $8,116,000 | – | 477,691 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |